138 results about "Plasmin activity" patented technology

A method for specifically removing or isolating plasmin(ogen) or plasmin in presence of fibrinogen from a mixture containing plasmin(ogen) or plasmin by contacting the mixture with a rigid amino acid wherein the amino group of the amino acid and the carboxylic group of the amino acid are about 6–8 Angstroms, preferably about 7 Angstroms apart and the rigid amino acid is covalently bound to the support via the amino group of the amino acid.

The product of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide having a plasmin peptide substrate of 2-4 amino acids and mono- or di-peptide linkage, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by plasmin. Also disclosed are methods of making and using the prodrug compounds.

A method is disclosed for creating a separation of posterior cortical vitreous from the retina of the eye. The method includes the step of introducing plasmin into the vitreous humor of the eye. The plasmin may be introduced either by injection or through a sustained release device. Optionally, other enzymes, polysaccharides, and/or glycoproteins are intermixed with the plasmin.

Heparin-binding regions of several proteins, such as neural cell adhesion molecule, fibronectin, laminin, midkine, and anti-thrombin III have been shown to promote neurite extension on two-dimensional surfaces. The effect of heparin-binding peptides on neurite extension through three-dimensional matrices was investigated by culturing embryonic chick dorsal root ganglia (DRG) within fibrin gels containing chemically attached heparin-binding peptide (HBP). The length of neurites within fibrin gels containing cross-linked HBP was increased by more than 70% over extension through fibrin gels containing no peptide. The HBP sequence of antithrombin III was incorporated into the fibrin gel as the C-terminal domain of a bidomian, chimeric peptide; the N-terminal second domain of this peptide contained the ∀2-plasmin inhibitor substrate for Factor XIIIa. Factor XIIIa, a transglutaminase, was used to chemically attach the HBP-containing chimeric peptide to the fibrin gels during polymerization. The amount of HBP cross-linked into the fibrin gels was determined, after degradation by plasmin using gel permeation chromatography, to be approximately 8 moles of peptide per mole fibrinogen. A peptide (HBP), where the cross-linking glutamine was replaced with glycine, showed no increase in extension in comparison with fibrin gels. The additional of heparin to the gel percursors resulted in no increase in neurite extension in comparison with fibrin gels. HBPs promote neurite extension by binding to cell surface proteoglycans on the DRG.

A non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy to the proliferative form of diabetic retinopathy comprising intravitreally administering to a patient suffering from non-proliferative diabetic retinopathy an effective amount of serine proteinase enzyme sufficient to create, without surgery, a posterior vitreal detachment to prevent or reduce the progression of proliferative diabetic retinopathy in said patient. Also disclosed is a non-surgical method of treating ocular conditions such as retinal ischemia, retinal inflammation, retinal edema tractional retinal detachment, tractional retinopathy, vitreous hemorrhage and tractional maculopathy by intravitreally administering to a patient suffering from one or more of these conditions with an effective amount of a serine proteinase enzyme to reduce or treat that particular ocular condition. Plasmin, microplasmin and miniplasmin are preferred serine proteinase enzymes and plasmin is the most preferred.

The invention relates to a process for the production of well-preserving lactose-free and low-lactose milk products. The process of the invention is characterized by separating the sugars and proteins in a raw material, thermally treating them in such a manner that the plasmin enzyme system and other proteolytic enzymes are inactivated, and combining the fractions and other preparation agents into a drink with a required composition and properties.

PCT No. PCT/JP97/01639 Sec. 371 Date Jan. 15, 1998 Sec. 102(e) Date Jan. 15, 1998 PCT Filed May 15, 1997 PCT Pub. No. WO97/43315 PCT Pub. Date Nov. 20, 1997A monoclonal antibody which specifically reacts with D-monomer produced by digesting human fibrinogen with granulocyte elastase and D-domain containing digestion products produced by digesting human stabilized fibrin with granulocyte elastase, but does not react with fibrinogen, or fragment X, Y or E produced by digesting fibrinogen with granulocyte elastase is disclosed. The D-dimer or DD/E complex produced by digestion with granulocyte elastase in a sample from a living body can be analyzed without being interferred with fibrinogen, digestion products of fibrinogen with plasmin, or digestion products of stabilized fibrin with plasmin, using the monoclonal antibody.

The invention relates to the preparation field of alcoholic beverage, in particular to gingko wine preparation with high health care component content, which is produced by taking deserted ginkgo biloba sarcotesta as the raw material, and adopting biological enzyme degrading pectic substance, cellulose, amylum, and other substances, and adopting the processes of wine yeast and natural grape fermentation or off-flavor alcohol infusing after enzyme destruction and defecation. The problems of foreign flavor and toxic component are simultaneously solved. The health care function of the gingko wine is more powerful than that of grape wine, the wine body is unique, the fruit aroma is stronger, the gingko wine is golden-colored and full of nutriments, with pure taste; and the gingko wine has the effects of dilating coronary arteries, enhancing blood flow, inhibiting blood coagulation, activating plasmin system, improving cardiotrophin, promoting cholesterin conversion, maintaining blood vessel elasticity, preventing and treating thromboembolia, coronary heart disease, angina pectoris, cerebral vasospasm and preventing cancer and restraining cancer, and the like. The gingko wine has remarkable economic benefit and social benefit.

A method of detecting an inflammatory disease or a cancer in a test subject comprising determining the amount of plasmenyl-PE or a biomarker having a mass charge ratio of approximately 698.2, 722.2, 726.2 or 750.2 in a sample of bodily fluid taken from the test subject and comparing the amount of plasmenyl-PE (or the biomarker) in the sample of the bodily fluid from the test subject to a range of amounts of plasmenyl-PE (or the biomarker) found in samples of the bodily fluid from a group of normal subjects of the same species as the test subject and lacking the inflammatory disease or the cancer, whereby a change in the amount of the plasmenyl-PE (or the biomarker) (such as a lower amount) in the sample of the bodily fluid from the test subject indicates the presence of the inflammatory disease or the cancer.

The invention discloses a method for separating and purifying the plasmin component in an animal medicine by a membrane separation technology and preparing a traditional Chinese medicine composition by use of the component. The method comprises the following steps: (1) weighing a proper quantity of ants or ground beeltles, and crushing into coarse powder; (2) soaking the coarse powder in water of which the amount is 6 times that of the coarse powder, and stirring to obtain homogenate; and fetching the homogenate and placing in a constant-temperature water bath, and stirring; (3) centrifuging and discarding the precipitate; (4) filtering the centrifugate with a pore membrane; (5) performing ultrafiltration concentration of the filtrate with an ultrafilter (molecular weight cut-off is 3,000-20,000) until the volume ratio of the medicine to the medicine liquid is about 1:1; and freeze-drying the concentrated liquid into powder for later use; and (6) independently using the freeze-dried powder or matching the freeze-dried powder with other components to obtain a composition for use. The invention provides a new method for separating and purifying the plasmin component in the animal medicine; and the extraction process is simple, and the effect is remarkable.

The invention discloses a method for culturing cordyceps militaris mycelium and plasmin. The used cordyceps militaris bacterial strain has a preservation number of CGMCC No.2577 in the General Microbiological Center of China Committee of Culture Collection for Microorganisms on 4th, July, 2008. The taxology name is cordyceps militaris. The culture method comprises bacterial classification activation, seed nutrient solution preparation and solid fermentation, a solid fermentation matrix contains cordyceps militaris and plasmi, its plasmin vitality can reach 927.77U/g. The method uses rice and wheat bran as culture matrix for culturing cordyceps militaris and producing cordyceps militaris mycelium and plasmin, bacterial classification and production raw material are safe and reliable, the raw material has the advantages of low cost and easy acquisition, compared with a traditional cultivation technology, the production period is shortened by 5/6, operation is simple, and realization is easy. The method provides a novel thinking and research base for research and development of health food for preventing and treating pulmonary thromboembolism, and provides a novel approach for producing cordyceps militaris mycelium.

The invention discloses a cDNA sequence and an amino acid sequence of coding lugworm fibrinolytic enzyme which are respectively shown in SEQIDNo.1 and SEQIDNo.2 in a sequence table, and belongs to the field of medical biological engineering. The cDNA sequence has the beneficial effects that according to the cDNA sequence of the lugworm fibrinolytic enzyme, the coding gene of the fibrinolytic enzyme can be cloned from digestive tract tissue of lugworm, and can be expressed in a prokaryotic expression system or a eukaryotic expression system through a gene recombination technology. The recombinant lugworm fibrinolytic enzyme has plasminogen activation activity, and can be used as a new thrombolytic medicament in genetic engineering.

A process is disclosed for liquefying the vitreous humor of an eye. The process includes the steps of delivering plasmin into the vitreous of the eye and incubating the vitreous and plasmin together for a period of time. Plasmin may be introduced through injection or a sustained release device. Plasmin may be used to treat a pathological condition of the eye such as diabetic retinopathy, macular hole, macular pucker, intraocular infection, foreign intraocular material and retinal detachment.

The present invention relates to one kind of and its culturing and preparing process. The plasmin is prepared with N. sitophila strain No. 17 in the preservation number of CGMCC No. 1836, and through fermentation, separation and purification. It consists of two subunits of molecular weight 30000 and 15500 separately and isoelectric point of 7.9+/-0.2. The plasmin has high thrombolysis performance, no bleeding activity, no blood coagulating activity and no obvious acute toxicity, and thus possesses clinical test, development and application foreground. The plasmin of the present invention is one kind of extracellular enzyme, and is favorable to post separation and purification. Its preparation adopts wheat bran and soybean residue as main culture medium material, and thus has low material cost.

The present invention relates to the extraction of fibrinolysin as new type of thromboliytic medicine from rhizopchin. The fibrinolysin has molecular weight 30.5 KD, isoelectric point 8.5, and double effects of directly dissolving thrombus and activating human plasminogen. The production process includes three stages, of culture of rhizopchin including slant culture, seed culture and fermentation culture; and separating and purifying fermented liquid to obtain fibrinolysin. The product is safe, non-toxic and cheap and the production process uses cheap agricultural side product as main material and is a liquid fermentation process. The purification process includes microfiltering to eliminate thallus, decolorizing with ion exchange resin, salting out, ultrafiltering to eliminate salt and hybrid protein and ion exchanging to purify. The present invention has short technological process, low cost and high production efficiency.

The invention relates to an ocean invertebrate plasmin which is a protein obtained by steps of homogenizing an ocean Sipunculus nudus digestive gland fluid, filtering to remove grease, freeze-drying, salting-out, desalinizing and carrying out DEAE chromatography and gel filtration chromatography. Amino acid sequence of the N-terminal part is Seq.2, and molecular weight is 15 KDa. It proves through experiment research that the plasmin has good effects of resisting thrombus and preventing and curing stroke.

The invention relates to protein earthworms EP-2, as well as its methods and applications. The disclosed earthworms protein EP-2 is based on fresh Eiseniafoetida as raw materials. The said method includes extracting by water-buffer homogenate, precipitating with precipitant, purifying with weak anion exchange resin to obtain a mixture of proteins, including protein F-I-0 and F-I-1 and fibrinolytic enzyme A component of 30%-40%. The earthworms protein EP-2 has a significant role in anti-asthma, and is a kind of active proteins with high medicinal value.